Press Releases Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
5.23 ^USD	+4.60%		-0.57%	-7.43%

09/05	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/05	Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	16/05	AQ
Monte Rosa Therapeutics : Corporate Presentation - May 2024	09/05	PU
Monte Rosa Therapeutics: Q1 Earnings Snapshot	09/05	AQ
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	09/05	AQ
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer	03/05	AQ
Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer	03/04	PU
Monte Rosa Therapeutics: Q4 Earnings Snapshot	14/03	AQ
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	14/03	AQ
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor	11/03	AQ
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	31/01	AQ
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024	08/01	AQ
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	AQ
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference	21/11	AQ
Monte Rosa Therapeutics: Q3 Earnings Snapshot	09/11	AQ
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	09/11	AQ
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases	07/11	AQ
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	27/23/27	AQ
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules	27/23/27	AQ
Monte Rosa Therapeutics : Company Call Presentation - October 17 2023	17/23/17	PU
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors	17/23/17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Press Releases

Filters